Rifabutin

Active ingredient: Rifabutin

In short: Rifabutin capsules are indicated for the prevention of disseminated Mycobacterium aviumcomplex (MAC) disease in patients with advanced HIV infection.

LabelRemedyrepack Inc.
Label updatedNov 11, 2026

What is Rifabutin used for?

Rifabutin capsules are indicated for the prevention of disseminated

Mycobacterium aviumcomplex (MAC) disease in patients with advanced HIV infection.

âš  Boxed warning (FDA's strongest warning)

Tuberculosis

Rifabutin capsules must not be administered for MAC prophylaxis to patients with active tuberculosis. Patients who develop complaints consistent with active tuberculosis while on prophylaxis with rifabutin should be evaluated immediately, so that those with active disease may be given an effective combination regimen of anti-tuberculosis medications. Administration of rifabutin as a single agent to patients with active tuberculosis is likely to lead to the development of tuberculosis that is resistant both to rifabutin and to rifampin.

There is no evidence that rifabutin is an effective prophylaxis against

M. tuberculosis. Patients requiring prophylaxis against both

M. tuberculosisand

Mycobacterium aviumcomplex may be given isoniazid and rifabutin concurrently.

Tuberculosis in HIV-positive patients is common and may present with atypical or extrapulmonary findings. Patients are likely to have a nonreactive purified protein derivative (PPD) despite active disease. In addition to chest X-ray and sputum culture, the following studies may be useful in the diagnosis of tuberculosis in the HIV-positive patient: blood culture, urine culture, or biopsy of a suspicious lymph node.

MAC Treatment with Clarithromycin

When rifabutin is used concomitantly with clarithromycin for MAC treatment, a decreased dose of rifabutin is recommended due to the increase in plasma concentrations of rifabutin .

Hypersensitivity and Related Reactions

Hypersensitivity reactions may occur in patients receiving rifamycins. …

Rifabutin dosage

It is recommended that rifabutin capsules, USP be administered at a dose of 300 mg once daily. For those patients with propensity to nausea, vomiting, or other gastrointestinal upset, administration of rifabutin at doses of 150 mg twice daily taken with food may be useful. Doses of rifabutin may be administered mixed with foods such as applesauce.

For patients with severe renal impairment (creatinine clearance less than 30 mL/min), consider reducing the dose of rifabutin by 50%, if toxicity is suspected. No dosage adjustment is required for patients with mild to moderate renal impairment. Reduction of the dose of rifabutin may also be needed for patients receiving concomitant treatment with certain other drugs .

Mild hepatic impairment does not require a dose modification. The pharmacokinetics of rifabutin in patients with moderate and severe hepatic impairment is not known.

Warnings & precautions

Do not take this medicine if: Rifabutin capsules are contraindicated in patients who have had clinically significant hypersensitivity to rifabutin or to any other rifamycins.

Rifabutin capsules are contraindicated in patients being treated with cabotegravir/rilpivirine prolonged-release injectable suspension .

Because treatment with rifabutin capsules may be associated with neutropenia, and more rarely thrombocytopenia, physicians should consider obtaining hematologic studies periodically in patients receiving prophylaxis with rifabutin.

Patients should be advised of the signs and symptoms of both MAC and tuberculosis, and should be instructed to consult their physicians if they develop new complaints consistent with either of these diseases. In addition, since rifabutin may rarely be associated with myositis and uveitis, patients should be advised to notify their physicians if they develop signs or symptoms suggesting either of these disorders.

Urine, feces, saliva, sputum, perspiration, tears, and skin may be colored brown-orange with rifabutin and some of its metabolites. Soft contact lenses may be permanently stained. Patients to be treated with rifabutin should be made aware of these possibilities.

Diarrhea is a common problem caused by antibacterials which usually ends when the antibacterial is discontinued. Sometimes, after starting treatment with antibacterials, patients can develop watery and bloody stools (with or without stomach cramps and fever) even as late as two or more months after having taken the last dose of the antibacterial. If this occurs, patients should contact their physician as soon as possible.

Repackaged By / Distributed By: RemedyRepack Inc. …

Rifabutin side effects

Adverse Reactions from Clinical Trials

Rifabutin capsules were generally well tolerated in the controlled clinical trials. Discontinuation of therapy due to an adverse event was required in 16% of patients receiving rifabutin, compared to 8% of patients receiving placebo in these trials. Primary reasons for discontinuation of rifabutin were rash (4% of treated patients), gastrointestinal intolerance (3%), and neutropenia (2%).

The following table enumerates adverse experiences that occurred at a frequency of 1% or greater, among the patients treated with rifabutin in studies 023 and 027.

Table: 3 Clinical Adverse Experiences Reported in ≥1% of Patients Treated With Rifabutin

Adverse event | Rifabutin

(n = 566) % | Placebo

(n = 580) %

Body as a whole

Abdominal pain | 4 | 3

Asthenia | 1 | 1

Chest pain | 1 | 1

Fever | 2 | 1

Headache | 3 | 5

Pain | 1 | 2

Blood and lymphatic system

Leucopenia | 10 | 7

Anemia | 1 | 2

Digestive System

Anorexia | 2 | 2

Diarrhea | 3 | 3

Dyspepsia | 3 | 1

Eructation | 3 | 1

Flatulence | 2 | 1

Nausea | 6 | 5

Nausea and vomiting | 3 | 2

Vomiting | 1 | 1

Musculoskeletal system

Myalgia | 2 | 1

Nervous system

Insomnia | 1 | 1

Skin and appendages

Rash | 11 | 8

Special senses

Taste perversion | 3 | 1

Urogenital system

Discolored urine | 30 | 6

CLINICAL ADVERSE EVENTS REPORTED IN <1% OF PATIENTS WHO RECEIVED RIFABUTIN

Considering data from the 023 and 027 pivotal trials, and from other clinical studies, rifabutin appears to be a likely cause of the following …

About this medicine

Rifabutin Capsules, USP for oral administration contain 150 mg of the rifamycin antimycobacterial agent rifabutin, USP, per capsule along with the inactive ingredients, microcrystalline cellulose, sodium lauryl sulfate, colloidal silicon dioxide, magnesium stearate. The hard gelatin capsule contains titanium dioxide, red iron oxide, gelatin, sodium lauryl sulfate and purified water. The imprinting ink contains shellac, dehydrated alcohol, isopropyl alcohol, butyl alcohol, propylene glycol, strong ammonia solution, black iron oxide, potassium hydroxide and purified water.

The chemical name for rifabutin is 1',4-didehydro-1-deoxy-1,4-dihydro-5'-(2-methylpropyl)-1-oxorifamycin XIV (Chemical Abstracts Service, 9th Collective Index) or (9

S,12

E,14

S,15

R, 16

S,17

R,18

R,19

R,20

S,21

S,22

E, 24

Z)-6,16,18,20-tetrahydroxy-1'-isobutyl-14-methoxy- 7,9,15,17,19,21,25-heptamethyl-spiro [9,4-(epoxypentadeca[1,11,13]trienimino)-2

H- furo[2',3':7,8]naphth[1,2-d] imidazole-2,4'-piperidine]-5,10,26-(3

H,9

H)-trione-16-acetate. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 754d2d7f-f0db-4f89-8fcd-5e2ff52d5030. Read the full official label on DailyMed.